HealthDay News — The overall prevalence of venous thromboembolism (VTE) in patients with COVID-19 is estimated to be 14.1%, with a higher prevalence for patients in the intensive care unit (ICU), according to a review published online Sep. 25 in Research and Practice in Thrombosis and Haemostasis.
Stephan Nopp, M.D., from the Medical University of Vienna, and colleagues conducted a systematic literature search to estimate the prevalence of VTE in patients with COVID-19. Data were identified from 86 studies with 33,970 patients; 66 studies with 28,173 patients were included in a quantitative analysis.
The researchers found that the overall prevalence estimate for VTE was 14.1%; the prevalence estimate was 40.3% with ultrasound screening and 9.5% without screening. High heterogeneity was seen in a subgroup analysis, with a VTE prevalence of 7.9 and 22.7% in non-ICU and ICU patients, respectively. The prevalence of pulmonary embolism was 3.5 and 13.7% in non-ICU and ICU patients, respectively. Higher D-dimer levels were seen in patients developing VTE versus non-VTE patients (weighted mean difference, 3.26 µg/mL).
“There is a clinical need for further research to better understand the risk and prevent VTE in patients with COVID-19,” the authors write. “These findings support the broad use of thromboprophylaxis, specifically in ICU patients.”
Several authors disclosed financial ties to the pharmaceutical industry.